Everything below concerns PPARδ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
== Strength == The strength of the adhesion between two materials depends on which of the above mechanisms occur between the two materials, and the surface area over which the two materials contact. Materials that wet against each other tend to have a larger contact area than those that do not. Wetting depends on the surface energy of the materials. Low surface energy materials such as polyethylene, polypropylene, polytetrafluoroethylene and polyoxymethylene are difficult to bond without special surface preparation. Another factor determining the strength of an adhesive contact is its shape. Adhesive contacts of complex shape begin to detach at the "edges" of the contact area. The process of destruction of adhesive contacts can be seen in the film. Recent experimental work has shown that adhesion-force measurements often exhibit non-Gaussian variability, and in some cases the normalized force distribution can be accurately represented using a Beta distribution.
== External links == Overview at colostate.edu Secretin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Nosek TM. "Section 6/6ch2/s6ch2_17". Essentials of Human Physiology. Archived from the original on 2016-03-24.
The side effects of ketoconazole are sometimes harnessed in the treatment of non-fungal conditions. While ketoconazole blocks the synthesis of the sterol ergosterol in fungi, in humans, at high dosages (>800 mg/day), it potently inhibits the activity of several enzymes necessary for the conversion of cholesterol to steroid hormones such as testosterone and cortisol. Specifically, ketoconazole has been shown to inhibit cholesterol side-chain cleavage enzyme, which converts cholesterol to pregnenolone, 17α-hydroxylase and 17,20-lyase, which convert pregnenolone into androgens, and 11β-hydroxylase, which converts 11-deoxycortisol to cortisol. All of these enzymes are mitochondrial cytochrome p450 enzymes. Based on these antiandrogen and antiglucocorticoid effects, ketoconazole has been used with some success as a second-line treatment for certain forms of advanced prostate cancer and for the suppression of glucocorticoid synthesis in the treatment of Cushing's syndrome. However, in the treatment of prostate cancer, concomitant glucocorticoid administration is needed to prevent adrenal insufficiency. Ketoconazole has additionally been used, in lower dosages, to treat hirsutism and, in combination with a GnRH analogue, male-limited precocious puberty. In any case, the risk of hepatotoxicity with ketoconazole limits its use in all of these indications, especially in those that are benign such as hirsutism. Ketoconazole has been used to prevent the testosterone flare at the initiation of GnRH agonist therapy in men with prostate cancer.
The two substrates of this enzyme are 4-hydroxybutanoic acid, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are succinic semialdehyde, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 4-hydroxybutanoate:NAD+ oxidoreductase. This enzyme is also called gamma-hydroxybutyrate dehydrogenase. This enzyme participates in butanoate metabolism and the degradation of the neurotransmitter 4-hydroxybutanoic acid.
Natural viral diseases, such as myxomatosis and rabbit hemorrhagic disease, have been used to help control pest populations. Over time the surviving pests become resistant, leading researchers to look at alternative methods. Genetically modified viruses that make the target animals infertile through immunocontraception have been created in the laboratory as well as others that target the developmental stage of the animal. There are concerns with using this approach regarding virus containment and cross species infection. Sometimes the same virus can be modified for contrasting purposes. Genetic modification of the myxoma virus has been proposed to conserve European wild rabbits in the Iberian peninsula and to help regulate them in Australia. To protect the Iberian species from viral diseases, the myxoma virus was genetically modified to immunize the rabbits, while in Australia the same myxoma virus was genetically modified to lower fertility in the Australian rabbit population. Outside of biology scientists have used a genetically modified virus to construct a lithium-ion battery and other nanostructured materials. It is possible to engineer bacteriophages to express modified proteins on their surface and join them up in specific patterns (a technique called phage display). These structures have potential uses for energy storage and generation, biosensing and tissue regeneration with some new materials currently produced including quantum dots, liquid crystals, nanorings and nanofibres.
Sources: en.wikipedia.org
=== New Zealand and Australia === Sales of A1 protein-free milk in Australia and New Zealand boosted significantly following 2007, after the publication of a book, Devil in the Milk by Keith Woodford, about A1 beta-casein and its perceived dangers to health; the book prompted the New Zealand Food Safety Authority to propose again reviewing the science to address consumer concerns that milk containing both the A1 and A2 proteins might be harmful. It asked the European Food Safety Authority (EFSA) to undertake such a review. The EFSA report, released in 2009, found that "a cause and effect relationship is not established between the dietary intake of BCM7 (beta-casomorphin-7), related peptides or their possible protein precursors and non-communicable diseases". The a2 Milk Company launched an infant formula in New Zealand and Australia in September 2013 and an A1 protein-free thickened cream was launched in January 2014 under the a2 and a2 MILK brands. A2 Corporation changed its name to the a2 Milk Company Limited effective April 2014, and at that time had about 8% market share of the milk products market in Australia. In 2014 Lion, a beverage and food company that operates in Australia and New Zealand and is owned by Kirin, relaunched its Pura Milk product with a new label stating: "Naturally contains A2 protein." The a2 Milk Company announced in November 2014 that it had begun the application process for a dual listing on the Australian Securities Exchange in a bid to open its register to Australian investors and boost the liquidity of its shares.
NATO responded in March 1999 by ordering airstrikes against Yugoslav military targets and infrastructure, including roads, railroads, administrative buildings and the headquarters of Radio Television Serbia. NATO's bombing campaign was not approved by the UN Security Council, for fear of a veto by Russia, which would cause controversy as to its legality. The UN Security Council adopted United Nations Security Council Resolution 1160, renewing arms and oil sanctions against the FR Yugoslavia, and thus crippling its economy. The effects of continuous aerial bombardment and sanctions cost the Yugoslav economy hundreds of billions of USD and eventually forced Milošević's government to comply with an agreement put forward by an international delegation. United Nations Security Council Resolution 1244 led to substantial autonomy for Kosovo, and the establishment of a UN mission to Kosovo, as well as the complete withdrawal of units of the Yugoslav National Army. As such, Kosovo remained an Autonomous Province of Serbia, but politically and economically independent. The damage to The FR Yugoslavia was immense, with the government estimating $100 billion in infrastructure damage, as well as 1,200 Serbian and Albanian civilians or soldiers confirmed dead. Economists have estimated at least $29 billion in direct damages caused by the bombings. In the aftermath of the Kosovo War, a low level insurgency continued in the Presevo valley in southern Serbia, which had Albanian minorities.
If an anaphylactoid reaction occurs the acetylcysteine is temporarily halted or slowed and antihistamines and other supportive care is administered. For example, a nebulised beta-agonist like salbutamol may be indicated in the event of significant bronchospasm (or prophylactically in patients with a history of bronchospasm secondary to acetylcysteine). It is also important to closely monitor fluids and electrolytes.
Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease. It reached Phase III clinical trials, but development was discontinued in 1996.
=== Management === The management of uterine prolapse may be conservative or surgical, depending on factors such as personal preference, symptom severity, and extent of prolapse. Additionally, management of existing medical conditions that can contribute to prolapse, such as chronic lung conditions or obesity, are important to prevent progression of uterine prolapse and reduce symptom burden.
Sources: en.wikipedia.org
== Worldview == Democratic Left advocated for a pluralist and socialist society that it considered "incompatible with the structures and values of capitalism." Although initially conceived as a political party, the organisation abandoned plans to field candidates and instead endorsed tactical voting strategies against the Conservative Party during the 1992 general election, subsequently evolving into a non-partisan campaigning organisation. The organisation pursued a broad range of progressive causes, including trade union modernisation through its Unions21 initiative, anti-racism and cultural diversity campaigns, democratic reform via the Make Votes Count campaign, and anti-poverty work through the Social Exclusion Network. Democratic Left emphasised coalition-building and functioned primarily as what scholars have described as a 'socialist anti-Conservative front'.
Evidence of the use of dye in pottery are found in most cases on the upper part of ceramic basins, on the inside surface, the areas in which the reduced dye-solution was exposed to air, and underwent oxidation that turned it purple. In the Late Bronze Age Hala Sultan Tekke on Cyprus was a major exporter of purple-dyed textiles with the dye coming from the mucus gland of the murex sea snail. The production of Murex purple for the Byzantine court came to an abrupt end with the sack of Constantinople in 1204, the critical episode of the Fourth Crusade. David Jacoby concludes that "no Byzantine emperor nor any Latin ruler in former Byzantine territories could muster the financial resources required for the pursuit of murex purple production. On the other hand, murex fishing and dyeing with genuine purple are attested for Egypt in the tenth to 13th centuries." By contrast, Jacoby finds that there are no mentions of purple fishing or dyeing, nor trade in the colorant in any Western source, even in the Frankish Levant. The European West turned instead to kermes dye provided by the insect Kermes vermilio, known as grana, or crimson. In 1909, Harvard anthropologist Zelia Nuttall compiled an intensive comparative study on the historical production of the purple dye produced from the carnivorous murex snail, source of the royal purple dye valued higher than gold in the ancient Near East and ancient Mexico.
Catatonia associated with autism spectrum disorder Catatonia associated with schizophrenia spectrum and other psychotic disorders Catatonia associated with brief psychotic disorder Catatonia associated with schizophreniform disorder Catatonia associated with schizoaffective disorder Catatonia associated with a substance-induced psychotic disorder Catatonia associated with bipolar and related disorders Catatonia associated with major depressive disorder Catatonic disorder due to another medical condition If catatonic symptoms are present but do not form the catatonic syndrome, a medication- or substance-induced aetiology should be considered first.
In January 1975, the Presidency of the Socialist Republic of Serbia requested a revision of constitutional solutions with explanation that the constitution divided the republic into three parts, thus preventing Serbia from exercising its "historic right to a nation state in the Yugoslav federation". Furthermore, the study Marković requested was completed in 1977 and was named The Blue Book. Although there were differing opinions in the state leadership on the position of the provinces – for example, Edvard Kardelj supported the demands of Serbian leaders – the result of the arbitration was the conclusion that the position of the provinces within Serbia should not be changed. The Federal leadership, led by Tito, believed that the constitutional solution from 1974 could satisfy all the claims of the Socialist Republic of Serbia, but also respect the specifics and special interests of the autonomous provinces. Although the conflict was (temporarily) pacified in this way, the issue remained unresolved. For most of its existence in the SFRY, Serbia was loyal and generally subordinate to the federal government. This changed after the death of Josip Broz Tito in 1980, when Albanian, as well as Serbian nationalism in Kosovo arose. In 1981, major protests erupted in Kosovo demanding the status of republic. The League of Communists was split on how to respond. At the same time, an economic crisis in Yugoslavia started. The leaders of the country were unable to carry out any reforms due to the political instability.
Lactalbumin, also known as "whey protein", is the albumin contained in milk and obtained from whey. Lactalbumin is found in the milk of many mammals. There are alpha and beta lactalbumins; both are contained in milk. Targeted small scientific studies suggest that certain types of lactalbumin (whey protein) may improve immune responsiveness and increase levels of glutathione systemically in animals and which apparently possess antiviral (against viruses), anti-apoptotic (impede cell death) and anti-tumor (against cancers or tumors) activities in humans, but larger and better studies are needed to confirm these attributions.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.